色久优优欧美色久优优_国产日韩综合av_91视频在线看_日韩va欧美va亚洲va久久_国产精品国产三级国产aⅴ中文_91视频观看免费_精品一区二区久久久_欧美一级xxx_波多野结衣中文字幕一区二区三区 _亚洲一线二线三线视频_日韩电影一二三区_欧美人与z0zoxxxx视频_亚洲地区一二三色_欧美性猛片xxxx免费看久爱_欧美日韩久久一区二区_91精品国产欧美一区二区成人

-- Indian companies granted license to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment of chronic hepatitis C -- NEW DELHI--(BUSINESS WIRE)--Sep. 15, 2014-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has signed non-exclusive licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C medicines in developing countries. The agreements allow the companies – Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd. – to manufacture sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 91 developing countries. The countries within the agreement account for more than 100 million people living with hepatitis C, representing 54% of the total global infected population. “Hepatitis C is a significant public health issue worldwide, and Gilead is working to make its chronic hepatitis C medicines accessible to as many patients, in as many places, as quickly as possible. In developing countries, large-volume generic manufacturing and distribution is widely regarded as a key component in expanding access to medicines. These agreements are essential to advancing the goals of our humanitarian program in these countries,” commented Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs, Gilead Sciences. Under the licensing agreements, the Indian companies receive a complete technology transfer of the Gilead manufacturing process to enable them to scale up production as quickly as possible. The licensees also set their own prices for the generic product they produce, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities. The licenses also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.